Congratulations to Prof. Denis Migliorini, holder of the ISREC Foundation Immuno-Oncology Chair. Together with Prof. Andrea Alimonti, he has been awarded a PHRT grant, supporting exceptional technological developments.

Among other things, Prof. Lana Kandalaft tells us about what led her to cancer research, about the development of cancer vaccines and what she is most passionate about in her work. Part of her research on cancer vaccines is supported by the ISREC Foundation.

Congratulations to Prof. Mikaël Pittet, who has been appointed full member of the Lausanne Branch of the Ludwig Institute for Cancer Research. The ISREC Foundation is proud to support a new generation of scientists who embody the hope for future breakthroughs in cancer research.

The BET Platform will contribute directly to realizing the vision for AGORA as a place that fosters cross-disciplinary interactions and cutting-edge innovation, with the ultimate goal of benefitting cancer patients more rapidly and efficiently.

The ISREC Foundation supports 5 students within the scope of the “Summer Research Program for Undergraduate Students” – EPFL School of Life Sciences, and 1 student in the “Summer Undergraduate Research Program” – Faculty of Biology and Medicine, University of Lausanne.
During these eight weeks of hands-on training, the selected young biologists or physicians are given the chance to discover the world of research for the very first time; a rewarding experience and the opportunity to establish new contacts on an international level.

Although significant scientific progress has been made and remission rates are steadily increasing, many cancer types remain incurable. Novel treatments, such as immunotherapy, could at least in part change this situation.

The ISREC Foundation and Lausanne University Hospital (CHUV) have announced that funding is now secured for the translation to the clinic of a leading-edge radiotherapy technology to treat the most resistant types of cancers. This innovative development in radiotherapy selectively kills tumour cells while sparing healthy tissues. Its successful entry into the clinic would be a first world-wide and could be used to treat a broad range of cancer patients with FLASH therapy. The 25 million Swiss Francs donation extends initial efforts pioneered by radiation oncology at CHUV and will enable its specialists to collaborate with CERN’s experts in accelerator technologies, to design and construct a dedicated FLASH radiotherapy platform.

This project is funded thanks to a private donation from the BILTEMA Foundation to the ISREC Foundation.

Learn more about the results of the work of Prof. Mikaël Pittet, holder of the ISREC Foundation’s Immuno-Oncology Chair at the UNIGE. These clarify the differences between the harmful side effects of immunotherapies and the desired immune responses designed to eliminate cancer cells. These findings provide a foundation for the development of more specific, more effective and less toxic therapeutic approaches.

Discover the work of Prof. Denis Migliorini, holder of the ISREC Foundation’s Brain Tumor Immunology Chair.

The ISREC Foundation has been promoting cancer research for more than fifty years. The work accomplished by the supported scientists over the past decades has led to a better understanding of the mechanisms underlying cancer and to the identification of novel therapeutic targets. Thanks to the newly built AGORA – Pôle de recherche sur le cancer, interdisciplinary exchanges are intensifying and will ultimately lead to more targeted advances and swifter breakthroughs in the improvement of cancer therapies.